|
1
|
Sacitharan PK: Ageing and osteoarthritis.
Subcell Biochem. 91:123–159. 2019.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kapoor M, Martel-Pelletier J, Lajeunesse
D, Pelletier JP and Fahmi H: Role of proinflammatory cytokines in
the pathophysiology of osteoarthritis. Nat Rev Rheumatol. 7:33–42.
2011.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Glyn-Jones S, Palmer AJ, Agricola R, Price
AJ, Vincent TL, Weinans H and Carr AJ: Osteoarthritis. Lancet.
386:376–387. 2015.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Abramoff B and Caldera FE: Osteoarthritis:
Pathology, diagnosis, and treatment options. Med Clin North Am.
104:293–311. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Xia B, Di C, Zhang J, Hu S, Jin H and Tong
P: Osteoarthritis pathogenesis: A review of molecular mechanisms.
Calcif Tissue Int. 95:495–505. 2014.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Redden RJ: Ketorolac tromethamine: An
oral/injectable nonsteroidal anti-inflammatory for postoperative
pain control. J Oral Maxillofac Surg. 50:1310–1313. 1992.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Vadivelu N, Gowda AM, Urman RD, Jolly S,
Kodumudi V, Maria M, Taylor R Jr and Pergolizzi JV Jr: Ketorolac
tromethamine-routes and clinical implications. Pain Pract.
15:175–193. 2015.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Jadhav PA and Yadav AV: Design,
development and characterization of ketorolac tromethamine
polymeric nanosuspension. Ther Deliv. 10:585–597. 2019.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Shrestha M, Chiu MJ, Martin RL, Cush JJ
and Wainscott MS: Treatment of acute gouty arthritis with
intramuscular ketorolac tromethamine. Am J Emerg Med. 12:454–455.
1994.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Shahi P, Kumari N and Pathak K:
Microspheres and tablet in capsule system: A novel
chronotherapeutic system of ketorolac tromethamine for site and
time specific delivery. Int J Pharm Investig. 5:161–170.
2015.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Beitzel K, McCarthy MB, Cote MP,
Apostolakos J, Russell RP, Bradley J, ElAttrache NS, Romeo AA,
Arciero RA and Mazzocca AD: The effect of ketorolac tromethamine,
methylprednisolone, and platelet-rich plasma on human chondrocyte
and tenocyte viability. Arthroscopy. 29:1164–1174. 2013.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Fan HW, Liu GY, Zhao CF, Li XF and Yang
XY: Differential expression of COX-2 in osteoarthritis and
rheumatoid arthritis. Genet Mol Res. 14:12872–12879.
2015.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lo V, Meadows SE and Saseen J: When should
COX-2 selective NSAIDs be used for osteoarthritis and rheumatoid
arthritis? J Fam Pract. 55:260–262. 2006.PubMed/NCBI
|
|
14
|
Bingham CO III: Development and clinical
application of COX-2-selective inhibitors for the treatment of
osteoarthritis and rheumatoid arthritis. Cleve Clin J Med. 69
(Suppl 1):SI5–S12. 2002.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Anderson GD, Hauser SD, McGarity KL,
Bremer ME, Isakson PC and Gregory SA: Selective inhibition of
cyclooxygenase (COX)-2 reverses inflammation and expression of
COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest.
97:2672–2679. 1996.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ratneswaran A, Rockel JS and Kapoor M:
Understanding osteoarthritis pathogenesis: A multiomics
system-based approach. Curr Opin Rheumatol. 32:80–91.
2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Lambova SN and Müller-Ladner U:
Osteoarthritis-current insights in pathogenesis, diagnosis and
treatment. Curr Rheumatol Rev. 14:91–97. 2018.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Johnson CI, Argyle DJ and Clements DN: In
vitro models for the study of osteoarthritis. Vet J. 209:40–49.
2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Geyer M and Schonfeld C: Novel insights
into the pathogenesis of osteoarthritis. Curr Rheumatol Rev.
14:98–107. 2018.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Sinha VR, Kumar RV and Singh G: Ketorolac
tromethamine formulations: An overview. Expert Opin Drug Deliv.
6:961–975. 2009.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Ketorolac for Pain Management: A Review of
the Clinical Evidence. CADTH Rapid Response Reports. Canadian
Agency for Drugs and Technologies in Health, Ottawa, ON, 2014.
|
|
23
|
Wojdasiewicz P, Poniatowski LA and
Szukiewicz D: The role of inflammatory and anti-inflammatory
cytokines in the pathogenesis of osteoarthritis. Mediators Inflamm.
2014(561459)2014.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Rahmati M, Mobasheri A and Mozafari M:
Inflammatory mediators in osteoarthritis: A critical review of the
state-of-the-art, current prospects, and future challenges. Bone.
85:81–90. 2016.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lv FH, Yin HL, He YQ, Wu HM, Kong J, Chai
XY and Zhang SR: Effects of curcumin on the apoptosis of
cardiomyocytes and the expression of NF-κB, PPAR-γ and Bcl-2 in
rats with myocardial infarction injury. Exp Ther Med. 12:3877–3884.
2016.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Hunter CA and Jones SA: Corrigendum: IL-6
as a keystone cytokine in health and disease. Nat Immunol.
18(1271)2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Yin J, Xia W, Li Y, Guo C, Zhang Y, Huang
S, Jia Z and Zhang A: COX-2 mediates PM2.5-induced apoptosis and
inflammation in vascular endothelial cells. Am J Transl Res.
9:3967–3976. 2017.PubMed/NCBI
|
|
28
|
Facchini A, Stanic I, Cetrullo S, Borzi
RM, Filardo G and Flamigni F: Sulforaphane protects human
chondrocytes against cell death induced by various stimuli. J Cell
Physiol. 226:1771–1779. 2011.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Lepetsos P and Papavassiliou AG:
ROS/oxidative stress signaling in osteoarthritis. Biochim Biophys
Acta. 1862:576–591. 2016.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Srivastava S, Saksena AK, Khattri S, Kumar
S and Dagur RS: Curcuma longa extract reduces inflammatory and
oxidative stress biomarkers in osteoarthritis of knee: A
four-month, double-blind, randomized, placebo-controlled trial.
Inflammopharmacology. 24:377–388. 2016.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Daheshia M and Yao JQ: The interleukin
1beta pathway in the pathogenesis of osteoarthritis. J Rheumatol.
35:2306–2312. 2008.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Nummenmaa E, Hamalainen M, Moilanen T,
Vuolteenaho K and Moilanen E: Effects of FGF-2 and FGF receptor
antagonists on MMP enzymes, aggrecan, and type II collagen in
primary human OA chondrocytes. Scand J Rheumatol. 44:321–330.
2015.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Wieland HA, Michaelis M, Kirschbaum BJ and
Rudolphi KA: Osteoarthritis-an untreatable disease? Nat Rev Drug
Discov. 4:331–344. 2005.PubMed/NCBI View
Article : Google Scholar
|
|
34
|
Gooljarsingh LT, Lakdawala A, Coppo F, Luo
L, Fields GB, Tummino PJ and Gontarek RR: Characterization of an
exosite binding inhibitor of matrix metalloproteinase 13. Protein
Sci. 17:66–71. 2008.PubMed/NCBI View Article : Google Scholar
|
